Kiwa Bio-Tech Products Group Closed New Equity Financing of $650,000

BEIJING and CLAREMONT, Calif., Feb. 22 /Xinhua-PRNewswire-FirstCall/ -- Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT) today reports a 5 million share equity investment by a new investor at the price of $0.13 per share. The shares are restricted. Details of the transaction are available in the 8K report filed by Kiwa with the SEC (www.sec.gov).

Mr. Wei Li, Chairman of the Board and CEO of the Company, stated, “This capital infusion will be used for further development of the marketing efforts for Kiwa’s bio-feed and bio-fertilizer businesses, development of the veterinary pharmaceuticals and research and development efforts. This will also strengthen the Company’s balance sheet and support the rapid growth we anticipate in 2008 and 2009.”

About Kiwa Bio-Tech Products Group Corporation

The Company develops, manufactures, distributes and markets innovative, cost-effective, and environmentally safe bio-technological products for agricultural and natural resources and environmental conservation. The Company has acquired the rights to manufacture and market AF-01 Anti-viral Aerosol Agent for use in preventing (blocking) bird-flu disease in Chinese and international markets. The Company has excellent relations with government authorities in China and has developed several innovative, high margin products, while continuing to grow through internal and external product development. The Company’s products are designed to enhance the quality of human life by increasing the value, quality and productivity of crops and decreasing the negative environmental impact of chemicals and other wastes. For more information about the Company, please review documents filed with the SEC (www.sec.gov) or visit the Company’s website at http://www.kiwabiotech.com .

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results described by the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release.

For more information, please contact:

Kiwa Bio-Tech Products Group Corporation

Yvonne Wang

Tel: 626-715-5855

Email: kiwabiotech@gmail.com

Robert Schechter

Equity Communications

Tel: 212-499-6809

Email: ir4kiwa@hotmail.com